Collagen : Director/PDMR Dealing

03 October 2019

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 2 October 2019, it granted awards ('Awards') over ordinary shares of 1 pence each in the share capital of the Company ('Shares') to the executive directors and other persons discharging managerial responsibility ('PDMRs') set out in the table below pursuant to the terms of its newly adopted deferred bonus plan (the 'DBP').

The DBP enables the Company to deliver some or all of an executive's annual bonus entitlement in the form of a right to acquire Shares, the vesting of which is normally conditional on continued employment over a specified period. No additional performance conditions have to be satisfied in order for Awards to vest.

The Awards listed in the table below relate to the bonuses earned by the relevant individuals in respect of the Company's financial year that ended on 31 March 2019. The number of Shares over which they have been granted was calculated by reference to a price per Share of 5.0p (being the price payable by investors under the Company's fundraising that completed in June 2019).

Director/PDMR	Position	Number of Shares over which Awards granted on 2 October 2019
Jamal Rushdy1	Chief Executive Officer	906,145
Lou Ruggiero1	Chief Business Officer	806,559
Hilary Spence2	Chief Financial Officer	336,000
Tom Hyland2	Chief Operating Officer	327,600
Chris Wattengel1	PDMR / VP Global R&D	246,514
Kevin Darling2	PDMR / VP Tissue Products	173,596

Notes:

1. This individual's Award has been granted as a 'conditional share award' in terms of which the relevant Shares will automatically be released to him/her, for no consideration, on vesting.
2. This individual's Award has been structured as a 'nil cost option' which has an exercise period of ten years from grant.

Each of the above Awards will normally vest on 9 July 2020 and it is anticipated that any Shares to which the individuals become entitled will be delivered by the Company's recently established employee benefit trust.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jamal Rushdy Lou Ruggiero Hilary Spence Tom Hyland Chris Wattengel Kevin Darling
2	Reason for the notification
a)	Position/status	Chief Executive Officer Chief Business Officer Chief Financial Officer Chief Operating Officer PDMR / VP Global R&D PDMR / VP Tissue Products
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Collagen Solutions plc
b)	LEI	213800IFY1CVGRGETL95
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1p each ('Shares') ISIN Code: GB00B94T6Y14
b)	Nature of the transaction	Grant of awards over Shares pursuant to the Collagen Solutions plc Deferred Bonus Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) 1. nil 906,145 2. nil 806,559 3. nil 336,000 4. nil 327,600 5. nil 246,514 6. nil 173,596
d)	Aggregated information - Aggregated volume - Price	N/A single transaction N/A single transaction N/A single transaction N/A single transaction N/A single transaction N/A single transaction
e)	Date of the transaction	2019-10-02
f)	Place of the transaction	Outside a trading venue

Enquiries:

Collagen Solutions Plc	Via Walbrook
Jamal Rushdy, CEO
Hilary Spence, CFO
Cenkos Securities Plc (Nominated Adviser and Broker)	Tel: [phone]
Giles Balleny Stephen Keys
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com